{"preliminary_commentary":{"by_channel":{"x_thread":8,"podcast":6,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02554812\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T20:56:46.727Z","note":"Automated from all 15 indexed sources (Jan 2024 – Aug 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":16,"text":"- Whether the combination improves overall survival\n- How toxicity affects use in the maintenance setting\n- Which patients may benefit, and whether biomarkers can identify them\n- How the combination fits alongside current first-line therapy\n\nAlso discussed: Trop-2 targeting."},"drugs_tested":[["avelumab","utomilumab"],["avelumab","ivuxolimab (PF-04518600)"],["avelumab","PD 0360324"]],"indication":"advanced malignancies","name":"JAVELIN Medley","nct_id":"NCT02554812","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=javelin-medley-nct02554812. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"NSCLC patients treated with avelumab + utomilumab (Dose level 1)","label":"Cohort A1","type":"EXPERIMENTAL"},{"description":"NSCLC patients treated with avelumab + utomilumab (Dose level 2)","label":"Cohort A2","type":"EXPERIMENTAL"},{"description":"NSCLC patients treated with avelumab + utomilumab (Dose level 3)","label":"Cohort A3","type":"EXPERIMENTAL"},{"description":"Melanoma patients treated with avelumab +utomilumab","label":"Cohort A4","type":"EXPERIMENTAL"},{"description":"SCCHN patients treated with avelumab + utomilumab","label":"Cohort A5","type":"EXPERIMENTAL"},{"description":"TNBC patients treated with avelumab + utomilumab","label":"Cohort A6","type":"EXPERIMENTAL"},{"description":"SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab","label":"Cohort A7","type":"EXPERIMENTAL"},{"description":"NSCLC first-line Stage IV treated with avelumab +PF-05082566","label":"Cohort A8","type":"EXPERIMENTAL"},{"description":"PF-04518600 + avelumab in selected tumor types","label":"Combination B Dose Escalation","type":"EXPERIMENTAL"},{"description":"PF-04518600 + avelumab in selected tumor types","label":"Combination B Expansion Cohorts","type":"EXPERIMENTAL"},{"description":"PD 0360324 + avelumab in selected tumor types","label":"Combination C Dose escalation cohorts","type":"EXPERIMENTAL"},{"description":"PD 0360324 + aveluamb in selected tumor types","label":"Combination C Dose expansion cohorts","type":"EXPERIMENTAL"},{"description":"PF-05082566 + PF-04518600 + avelumab in selected tumor types","label":"Combination D Dose escalation cohorts","type":"EXPERIMENTAL"},{"description":"PF-05082566 + PF-04518600 + avelumab in selected tumor types","label":"Combination D Dose expansion cohorts","type":"EXPERIMENTAL"},{"description":"NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)","label":"Cohort A9","type":"EXPERIMENTAL"},{"description":"NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)","label":"Cohort A10","type":"EXPERIMENTAL"},{"description":"CMP-001 +avelumab in SCCHN","label":"Cohort F1","type":"EXPERIMENTAL"},{"description":"CMP-001+avelumab+utomilumab in SCCHN","label":"Cohort F2","type":"EXPERIMENTAL"},{"description":"CMP-001 +avelumab+PF-04518600 in SCCHN","label":"Cohort F3","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-03-23","type":"ACTUAL"},"conditions":["Advanced Cancer"],"enrollment":{"count":409,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Avelumab","otherNames":["MSB0010718C"],"type":"DRUG"},{"name":"Utomilumab","otherNames":["PF-05082566"],"type":"DRUG"},{"name":"PF-04518600","otherNames":[],"type":"DRUG"},{"name":"PD 0360324","otherNames":[],"type":"DRUG"},{"name":"CMP-001","otherNames":[],"type":"DRUG"}],"last_update":"2024-07-30","lead_sponsor":"Pfizer","official_title":"A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-03-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1b Lead-in: Number of Participants With First 2 Cycles Dose Limiting Toxicity (DLT) for Combination A","timeFrame":"Baseline up to Cycle 2 (up to 8 weeks)"},{"measure":"Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination B","timeFrame":"Baseline up to Cycle 2 (up to 8 weeks)"},{"measure":"Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination C","timeFrame":"Baseline up to Cycle 2 (up to 8 weeks)"},{"measure":"Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination D","timeFrame":"Baseline up to Cycle 2 (up to 8 weeks)"},{"measure":"Phase 1b Lead-in: Number of Participants With First Cycle DLT for Combination F","timeFrame":"Baseline up to first Cycle (up to 4 weeks)"},{"measure":"Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment for Combination A","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 53 months approximately)"},{"measure":"Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination B","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (approximately 26 months)"}],"references":[],"start_date":{"date":"2015-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)","url":"https://clinicaltrials.gov/study/NCT02554812"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/javelin-medley-nct02554812"}